First Patient Enrolled in the US STEP-1 Clinical Trial of EndoBarrier at Michigan Medicine
(WorldNews Health)

BOSTON and SYDNEY - 28 January 2020 - GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States (U.S.) STEP-1 clinical trial has been enrolled at Michigan Medicine in Ann Arbor, Michigan. Michigan Medicine is one of five clinical study sites for the STEP-1 trial; the site is led by principal investigator Allison R. Schulman M.D., M.P.H., assistant professor of gastroenterology and internal medicine. `We are honored to be the first clinical study site to enroll the first patient into the STEP-1 trial,` said Dr. Schulman. `This groundbreaking trial is the...